Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A

By: TheNewswire.com
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Incannex Healthcare Ltd (ASX:IHL, NASDAQ: IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics and the safety of the company’s anti-inflammatory drug candidate IHL-675A. IHL-675A is a combination cannabinoid drug comprising cannabidiol (CBD) and hydroxychloroquine (HCQ) in a fixed dose combination.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  246.52
+6.17 (2.57%)
AAPL  338.50
-6.13 (-1.78%)
AMD  469.56
-35.24 (-6.98%)
BAC  49.67
-0.34 (-0.67%)
GOOG  279.45
+1.23 (0.44%)
META  608.68
-6.31 (-1.03%)
MSFT  508.67
-13.24 (-2.54%)
NVDA  202.10
-2.54 (-1.24%)
ORCL  118.84
-11.82 (-9.05%)
TSLA  402.20
+2.39 (0.60%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.